NCT06334367View on ClinicalTrials.gov

Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 26, 2024

Primary Completion Date

March 26, 2026

Study Completion Date

March 26, 2026

Conditions
GVHD
Interventions
DRUG

CD25 treatment

CD25 prophylaxis

DRUG

low-dose ATG

HSCT pre-treatment with 7.5mg/Kg ATG(2.5mg/Kg/d) at day -4, -3 and -2.

Trial Locations (1)

250021

Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan

All Listed Sponsors
lead

Wang Xin

OTHER_GOV